MedPage Today March 30, 2024
— FDA’s approval may be a step toward greater access
About 25 million people stand to gain from the FDA’s recent approval of the first over-the-counter continuous glucose monitor (CGM). That means fewer finger pricks and greater access for patients with type 2 diabetes who do not use insulin.
Soon, patients 18 and older will be able to purchase an electronic sensor that regularly monitors and records glucose trends, then analyzes the information in real time. We won’t know the cost of the device until it comes out this summer, but we do know that a lack of health insurance and prescriptions will no longer be barriers to patients who want to use it.
The Benefits of CGMs
Among patients...
Today's Sponsors
Today's Sponsor